| sPD-1 | P value | |
---|---|---|---|
High-level group n = 34 | Low-level group n = 24 | ||
Age (years, mean ± SD) | 66.0 ± 9.7 | 65.2 ± 9.0 | 0.689 |
Female, (n, %) | 22 (64.7) | 15 (62.5) | 0.863 |
Disease duration (months), median, IQR | 60 (12, 141) | 60 (36, 120) | 0.548 |
Smoking history, (n, %) | 9 (26.5) | 5 (20.8) | 0.621 |
RF titer (IU/ml), mean ± SD | 538.8 ± 1151.9 | 542.8 ± 928.1 | 0.989 |
Anti-CCP positive, mean ± SD | 32 (94.1) | 22 (91.7) | 0.717 |
ESR (mm/h), mean ± SD | 48.9 ± 34.1 | 53.5 ± 31.4 | 0.60 |
CRP (mg/dl), mean ± SD | 36.0 ± 51.1 | 29.3 ± 33.9 | 0.549 |
DAS28-ESR, mean ± SD | 4.5 ± 1.3 | 5.2 ± 1.7 | 0.105 |
HRCT score, mean ± SD | 6.2 ± 3.1 | 5.3 ± 3.7 | 0.319 |
CT-UIP (n, %) | 23(67.6) | 11(45.8) | 0.096 |
FVC%, mean ± SD | 82.5 ± 20.1 | 94.8 ± 15.2 | 0.022* |
DLCO%, mean ± SD | 58.4 ± 15.5 | 66.2 ± 20.6 | 0.201 |
Cough (n, %) | 21 (61.8) | 10 (41.7) | 0.131 |
Dyspnea (n, %) | 6 (17.6) | 3 (12.5) | 0.722 |
Chest tightness (n, %) | 14 (41.2) | 6 (25.0) | 0.202 |
Use of GCs (n, %) | 23 (67.6) | 21 (87.5) | 0.121 |
Use of MTX (n, %) | 6 (17.6) | 3 (12.5) | 0.722 |